Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]F-RESCA-WWH347 is a novel radiopharmaceutical probe designed for immunoPET imaging, specifically targeting the GPA33 antigen. It utilizes the Al^18^F-RESCA (Aluminum fluoride-restrained complexing agent) method to label heat-sensitive biomolecules with fluorine-18, enabling high-specificity PET imaging of tumors expressing GPA33, such as those found in colorectal and other digestive system cancers. The RESCA chelator allows for mild and efficient radiolabeling at room temperature, preserving the integrity of sensitive proteins or antibody fragments. This probe is being investigated primarily for its ability to visualize and quantify tumor burden in patients with digestive system carcinomas using immunoPET/CT scans[1][3][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]F-RESCA-WWH347.